Recent prospective trials for esophageal cancer, gastric cancer, and gastrointestinal stromal tumor (GIST) are encouraging. This manuscript reviews selected recently published studies. Not surprisingly, immunotherapy dominates the current clinical trial landscape. However, targeted biologic therapies and standard chemotherapy remain critical to the treatment of gastric and esophageal cancer while imatinib remains the backbone for advanced or metastatic GISTs. For all three cancers, surgical resection remains important when intent of treatment is potential cure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.27530 | DOI Listing |
Publication Analysis
Top Keywords
esophageal cancer
8
advances treatment
4
treatment upper
4
upper gastrointestinal
4
gastrointestinal malignancy
4
malignancy prospective
4
prospective trials
4
trials esophageal
4
cancer gastric
4
gastric cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!